SciSparc Has Received A Decision To Grant European Patent Number EP3484469 Titled "Compositions And Methods Of Potentiating Antimicrobials (Combined With Cannabinoids For Treatment Of Bacterial Infections)"
Portfolio Pulse from Benzinga Newsdesk
SciSparc announced it has received a decision to grant European Patent Number EP3484469, titled 'Compositions And Methods Of Potentiating Antimicrobials (Combined With Cannabinoids For Treatment Of Bacterial Infections)'. This patent strengthens SciSparc's intellectual property portfolio, specifically in the area of using cannabinoids to enhance antimicrobial treatments.
March 06, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's receipt of the European Patent EP3484469 for cannabinoid-enhanced antimicrobial treatments could significantly bolster its intellectual property portfolio and potentially open up new avenues for product development and partnerships.
The granting of a European patent typically enhances a company's intellectual property portfolio, making it more attractive for partnerships and potentially leading to new product developments. For SciSparc, this patent could provide a competitive edge in the cannabinoid-based treatment market, possibly leading to increased investor interest and stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90